VHL and cancer: In breast cancer model it has been shown that HIF-1α as a regulator of CD44 that increased the number of CD44 molecules and the percentage of (variant exons v6 and v7/8) CD44 positive cells is higher in cancer cells in hypoxia41, which might also be true for RCC that is known to harbor VHL mutations.